Adherence to adjuvant endocrine therapy: Is it a factor for ethnic differences in breast cancer outcomes in New Zealand?

Breast

Volumn 24, Issue 1, 2015, Pages 62-67

  Seneviratne, Sanjeewa ^a   Campbell, Ian ^a   Scott, Nina ^b   Kuper Hommel, Marion ^b   Kim, Boa ^c   Pillai, Avinesh ^d   Lawrenson, Ross ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAIKATO DISTRICT HEALTH BOARD   (New Zealand)

^c WAIKATO HOSPITAL   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Breast cancer; Endocrine therapy; Ethnicity; Inequity; Medication adherence

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ETHNIC DIFFERENCE; EUROPEAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAORI (PEOPLE); MEDICATION COMPLIANCE; NEW ZEALAND; PATIENT COMPLIANCE; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CAUCASIAN; CHEMISTRY; ETHNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; OCEANIC ANCESTRY GROUP; PROSPECTIVE STUDY; REGISTER; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; REGISTRIES; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84920614775     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.11.011     Document Type: Article

References (34)

1. Cancer: new registrations and deaths 2009 [Internet] 2012, Ministry of Health, Wellington, New Zealand.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
3. Robson B., Purdie G., Cormack D. Unequal impact II: Maori and non-Maori cancer statistics by deprivation and rural-urban status 2002-2006 2010, Ministry of Health, Wellington.
4. Bramley D., Hebert P., Jackson R., Chassin M. Indigenous disparities in disease-specific mortality, a cross-country comparison: New Zealand, Australia, Canada, and the United States. NZ Med J 2004, 117(1207):U1215.
5. Soeberg M., Blakely T., Sarfati D., Tobias M., Costilla R., Carter K., et al. Cancer trends: trends in cancer survival by ethnic and socioeconomic group, New Zealand 1991-2004 [Internet] 2012, University of Otago and Ministry of Health, Wellington, New Zealand.
6. Seneviratne S., Campbell I., Scott N., Coles C., Lawrenson R. Treatment delay for Māori women with breast cancer in New Zealand. Ethn Health 2014, 1-16. [Epub ahead of print].
7. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784.
8. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11(12):1135-1141.
9. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381(9869):805-816.
10. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59(1):56-66.
11. Makubate B., Donnan P.T., Dewar J.A., Thompson A.M., McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 2013, 108(7):1515-1524.
12. Barron T.I., Connolly R., Bennett K., Feely J., Kennedy M.J. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007, 109(5):832-839.
13. Ma A.M., Barone J., Wallis A.E., Wu N.J., Garcia L.B., Estabrook A., et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 2008, 196(4):500-504.
14. Hershman D.L., Shao T., Kushi L.H., Buono D., Tsai W.Y., Fehrenbacher L., et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011, 126(2):529-537.
15. McCowan C., Shearer J., Donnan P.T., Dewar J.A., Crilly M., Thompson A.M., et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008, 99(11):1763-1768.
16. Seneviratne S., Campbell I., Scott N., Shirley R., Peni T., Lawrenson R. Accuracy and completeness of the New Zealand Cancer Registry for staging of invasive breast cancer. Cancer Epidemiol 2014, 38(5):638-644.
17. 2006 census data: New Zealand statistics 2007, Available from:. http://www.stats.govt.nz/17.
18. Ethnicity data protocols for the health and disability sector 2004, Ministry of Health, Wellington, [15/05/2014]. Available from:. http://www.health.govt.nz/publication/ethnicity-data-protocols-health-and-disability-sector.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40(5):373-383.
20. NZDep2006: Index of deprivation. Department of public health, university of Otago 2007, Ministry of Health, Wellington.
21. New Zealand: An urban/rural profile: Statistics New Zealand; [13/03/2014]. Available from:. http://www.stats.govt.nz/browse_for_stats/people_and_communities/Geographic-areas/urban-rural-profile.aspx.
22. AJCC cancer staging manual 2010, Springer-Verlag, New York. 7th ed.
23. Hadji P., Ziller V., Kyvernitakis J., Bauer M., Haas G., Schmidt N., et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013, 138(1):185-191.
24. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1):45-53.
25. Cormack D., Purdie G., Ratima M. Access for cancer services for Maori, a report prepared for the ministry of health 2005, Available from:. http://www.health.govt.nz/publication/access-cancer-services-maori.
26. Hill S., Sarfati D., Blakely T., Robson B., Purdie G., Dennett E., et al. Ethnicity and management of colon cancer in New Zealand: do indigenous patients get a worse deal?. Cancer 2010, 116(13):3205-3214.
27. Stevens W., Stevens G., Kolbe J., Cox B. Ethnic differences in the management of lung cancer in New Zealand. JThorac Oncol 2008, 3(3):237-244.
28. Jatrana S., Crampton P. Primary health care in New Zealand: who has access?. Health Policy 2009, 93(1):1-10.
29. Tatau Kahukura: maori health chart book 2010 2010, Ministry of Health, Wellington. 2nd ed.
30. Jatrana S., Crampton P., Norris P. Ethnic differences in access to prescription medication because of cost in New Zealand. JEpidemiol Community Health 2011, 65(5):454-460.
31. Jacob Arriola K.R., Mason T.A., Bannon K.A., Holmes C., Powell C.L., Horne K., et al. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 2014, 95(1):98-103.
32. Kickbusch I., Wait S., Maag D. Navigating health: the role of health literacy 2006, Alliance for Health and the Future, London.
33. Korero Mārama: health literacy and māori: results from the 2006 adult literacy and life skills survey 2010, Wellington, New Zealand.
34. Koay K., Schofield P., Jefford M. Importance of health literacy in oncology. Asia Pac J Clin Oncol 2012, 8(1):14-23.